2024: Future Endeavors
- Own laboratory in BioCube Berlin
- Acquisition of own Mass Spectrometry
- GRW Grant
About Us
Leading the Fight Against Cancer Through Innovative Immunotherapy Solutions
Alithea Biotechnology is at the forefront of innovative cancer treatment solutions. Our mission is to revolutionize cancer treatment by advancing T-cell mediated immunotherapies and leveraging our expertise in HLA peptide quantification to improve therapeutic efficacy and safety.
Our Mission
To revolutionize cancer treatment by advancing T-cell mediated immunotherapies and leveraging our expertise in HLA peptide quantification to improve therapeutic efficacy and safety.Our Vision
Alithea Bio envisions a world free from cancer, driven by our groundbreaking TCR therapies and extensive HLA peptide database to deliver safer, targeted treatments.Our History
Alithea Bio’s journey is marked by groundbreaking
discoveries and relentless dedication to cancer
treatment.
2023: Achievements
- Large deal signed with big pharma
- Revenues exceed expectations by Bundesministerium fur Wirtschaft und Klimaschutz
2022: Expanding Horizons
- Large deal signed with Swiss Biotech
- UK-GER grant
2021: Continued Growth
- Multiple deals with new and returning customers
2020: Major Milestones
- First commercial contracts completed
- Accelerator participation in BadenCampus and Zentrales Innovationsprogramm Mittelstand
Founded in Freiburg
- Founded in Freiburg
- Set up a lab at University of Strasbourg
Team
Tim Fugmann
Chief Scientific Officer and Co-Founder
Hagen Grauer
Chief Financial Officer and Co-Founder
Fanny Giannou
Founder and CEO
